Linden Thomas Advisory Services LLC Acquires 328 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Linden Thomas Advisory Services LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,945 shares of the company’s stock after acquiring an additional 328 shares during the quarter. IDEXX Laboratories accounts for about 0.6% of Linden Thomas Advisory Services LLC’s investment portfolio, making the stock its 14th largest position. Linden Thomas Advisory Services LLC’s holdings in IDEXX Laboratories were worth $3,300,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in IDXX. Patron Partners LLC lifted its holdings in shares of IDEXX Laboratories by 2.7% in the 4th quarter. Patron Partners LLC now owns 765 shares of the company’s stock worth $425,000 after acquiring an additional 20 shares during the last quarter. NewEdge Wealth LLC boosted its stake in shares of IDEXX Laboratories by 3.1% in the 4th quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock valued at $366,000 after purchasing an additional 20 shares in the last quarter. Phoenix Holdings Ltd. boosted its stake in shares of IDEXX Laboratories by 2.8% in the 3rd quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock valued at $338,000 after purchasing an additional 21 shares in the last quarter. BluePath Capital Management LLC boosted its stake in shares of IDEXX Laboratories by 1.8% in the 4th quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock valued at $663,000 after purchasing an additional 21 shares in the last quarter. Finally, Valley National Advisers Inc. boosted its stake in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the sale, the chief executive officer now directly owns 79,247 shares in the company, valued at $45,377,624.67. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,524 shares of company stock worth $24,871,960. 2.18% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group upped their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. Finally, Barclays upped their price target on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $591.50.

IDEXX Laboratories Trading Up 2.7 %

NASDAQ IDXX traded up $13.04 during trading on Tuesday, hitting $492.61. The company had a trading volume of 312,389 shares, compared to its average volume of 427,479. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a market cap of $40.91 billion, a price-to-earnings ratio of 47.62, a price-to-earnings-growth ratio of 3.67 and a beta of 1.26. The company’s fifty day moving average is $536.30 and its 200-day moving average is $510.27.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The business had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. During the same period in the prior year, the business earned $2.05 EPS. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.